BJL
RPRX icon

Brighton Jones LLC’s Royalty Pharma RPRX Stock Holding History

Brighton Jones LLC’s Portfolio RPRX Stock Details RPRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$418K Buy
7,453
+1,368
+22% +$71.2K 0.01% 881
2026
Q1 		$292K Buy
+6,085
New +$267K 0.01% 946

Other funds holding RPRX

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
Swedbank
Swedbank Stockholm, Sweden $116B AUM 46.87% 1-Year Est. Return
Baillie Gifford & Co
Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return
Amundi
Amundi Paris, France $413B AUM 44.57% 1-Year Est. Return
Victory Capital Management
Victory Capital Management San Antonio, Texas $178B AUM 37.23% 1-Year Est. Return
Deutsche Bank
Deutsche Bank Frankfurt Am Main Ge, Germany $344B AUM 42.99% 1-Year Est. Return
Nordea Investment Management
Nordea Investment Management Stockholm, Sweden $123B AUM 38.85% 1-Year Est. Return
NSCM
New South Capital Management Memphis, Tennessee $2.28B AUM 47.19% 1-Year Est. Return
Russell Investments Group
Russell Investments Group London, United Kingdom $114B AUM 41.71% 1-Year Est. Return

Brighton Jones LLC's RPRX Position: Q2 2026 in Review

Brighton Jones LLC increased its Royalty Pharma (RPRX) stake by 22% in Q2 2026, buying an estimated $71.2K and bringing the position to 7,453 shares worth $418K. The position accounts for 0.01% of the portfolio, ranked #881.

Brighton Jones LLC first reported a position in RPRX in Q1 2026 and has held it in 2 quarters since. 365 funds tracked by Wall St. Rank hold RPRX as of Q2 2026.

  • Brighton Jones LLC held 7,453 shares of Royalty Pharma worth $418K as of Q2 2026.
  • Brighton Jones LLC bought 1,368 Royalty Pharma shares in Q2 2026, an estimated $71.2K.
  • Royalty Pharma made up 0.01% of Brighton Jones LLC's portfolio in Q2 2026, its #881 holding.
  • Brighton Jones LLC first reported a position in Royalty Pharma in Q1 2026 and has held it in 2 quarters since.
  • 365 funds tracked by Wall St. Rank held Royalty Pharma as of Q2 2026.

Based on Brighton Jones LLC's 13F filing for Q2 2026, filed 11 Aug 2026.